Ao Guo , Ke Zheng , Wanqi Jia , Shengting Zhang , Cong Sui
{"title":"Circadian rhythm disturbance induces osteoarthritis in mice: Involvement of Clock and Bmal1 dysregulation and Pdgfa inhibition","authors":"Ao Guo , Ke Zheng , Wanqi Jia , Shengting Zhang , Cong Sui","doi":"10.1016/j.bcp.2025.117342","DOIUrl":null,"url":null,"abstract":"<div><div>Circadian rhythm disturbance (CRD) is likely associated with impaired bone development and the development of osteoarthritis (OA). This study investigates the functions of circadian locomotor output cycles kaput (<em>Clock</em>) and brain and muscle Arnt-like 1 (<em>Bmal1</em>) in OA progression and explores the implicated molecular mechanisms. Mice were subjected to CRD for 70 d. This led to significant OA-like symptoms, accompanied by a reduction in the expression of <em>Clock</em> and <em>Bmal1</em>. Either <em>Clock</em> or <em>Bmal1</em> upregulation reduced serum concentrations of inflammatory cytokines (interleukin [IL]-1β and IL-6) in mice, and it reduced cartilage erosion and extracellular matrix degradation in their knee joints, with parallel findings observed in the isolated chondrocytes <em>in vitro</em>. The Clock:Bmal1 heterodimer binds to the enhancer upstream of the <em>Pdgfa</em> promoter to enhance its transcription. <em>Pdgfa</em> knockdown reversed the protective effects of <em>Clock</em> and <em>Bmal1</em> by inactivating the Pi3k/Akt and Erk1/2 cascade. By contrast, <em>Pdgfa</em> overexpression reduced chondrocyte damage, which was, however, negated by the Pi3k/Akt inhibitor LY294002. Collectively, this study validates that CRD is pertinent to the development of OA. Restoring <em>Clock</em> and <em>Bmal1</em> levels may help ameliorate chondrocyte loss in CRD-associated OA by activating <em>Pdgfa</em> transcription and enhancing Pi3k/Akt and Erk1/2 signaling pathways.</div></div>","PeriodicalId":8806,"journal":{"name":"Biochemical pharmacology","volume":"242 ","pages":"Article 117342"},"PeriodicalIF":5.6000,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biochemical pharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0006295225006070","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Circadian rhythm disturbance (CRD) is likely associated with impaired bone development and the development of osteoarthritis (OA). This study investigates the functions of circadian locomotor output cycles kaput (Clock) and brain and muscle Arnt-like 1 (Bmal1) in OA progression and explores the implicated molecular mechanisms. Mice were subjected to CRD for 70 d. This led to significant OA-like symptoms, accompanied by a reduction in the expression of Clock and Bmal1. Either Clock or Bmal1 upregulation reduced serum concentrations of inflammatory cytokines (interleukin [IL]-1β and IL-6) in mice, and it reduced cartilage erosion and extracellular matrix degradation in their knee joints, with parallel findings observed in the isolated chondrocytes in vitro. The Clock:Bmal1 heterodimer binds to the enhancer upstream of the Pdgfa promoter to enhance its transcription. Pdgfa knockdown reversed the protective effects of Clock and Bmal1 by inactivating the Pi3k/Akt and Erk1/2 cascade. By contrast, Pdgfa overexpression reduced chondrocyte damage, which was, however, negated by the Pi3k/Akt inhibitor LY294002. Collectively, this study validates that CRD is pertinent to the development of OA. Restoring Clock and Bmal1 levels may help ameliorate chondrocyte loss in CRD-associated OA by activating Pdgfa transcription and enhancing Pi3k/Akt and Erk1/2 signaling pathways.
期刊介绍:
Biochemical Pharmacology publishes original research findings, Commentaries and review articles related to the elucidation of cellular and tissue function(s) at the biochemical and molecular levels, the modification of cellular phenotype(s) by genetic, transcriptional/translational or drug/compound-induced modifications, as well as the pharmacodynamics and pharmacokinetics of xenobiotics and drugs, the latter including both small molecules and biologics.
The journal''s target audience includes scientists engaged in the identification and study of the mechanisms of action of xenobiotics, biologics and drugs and in the drug discovery and development process.
All areas of cellular biology and cellular, tissue/organ and whole animal pharmacology fall within the scope of the journal. Drug classes covered include anti-infectives, anti-inflammatory agents, chemotherapeutics, cardiovascular, endocrinological, immunological, metabolic, neurological and psychiatric drugs, as well as research on drug metabolism and kinetics. While medicinal chemistry is a topic of complimentary interest, manuscripts in this area must contain sufficient biological data to characterize pharmacologically the compounds reported. Submissions describing work focused predominately on chemical synthesis and molecular modeling will not be considered for review.
While particular emphasis is placed on reporting the results of molecular and biochemical studies, research involving the use of tissue and animal models of human pathophysiology and toxicology is of interest to the extent that it helps define drug mechanisms of action, safety and efficacy.